Barclays analyst Luke Sergott raised the firm’s price target on Medpace (MEDP) to $525 from $485 and keeps an Underweight rating on the shares. The firm adjusted ratings and price targets in the life sciences and diagnostics tools space as part of its 2026 outlook. The last of the estimate cuts, recovering end markets and tools being the “most under-owned space in healthcare” creates a “great setup” for outperformance of the tools group in 2026, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MEDP:
- Jefferies says market thinking ‘backwards’ on FDA one trial proposal
- FDA shift in drug study requirements sends trial runners lower
- FDA to reduce number of trials required for drug approvals, STAT reports
- Medpace initiated with a Market Perform at BMO Capital
- Medpace Holdings Inc: Key Update on the OPAL Study for Lymphoid Malignancies